ADCY6

Across TCGA pan-cancer cohorts, ADCY6 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ADCY6’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ADCY6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ADCY6 is over-expressed in tumor, although a few such as COAD and HNSC show the opposite, repressed pattern.

LIHC, COAD, and HNSC are the cancer types where ADCY6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADCY6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+2.002	<.001	9	view →
COAD	Female	II,III,IV	−0.622	<.001	7	view →
HNSC	All	All	−0.572	.001	7	view →
LUSC	All	II,III,IV	−1.107	<.001	6	view →
KICH	All	All	−0.920	<.001	6	view →
BRCA	Female	All	−0.754	<.001	6	view →
KIRC	Male	II,III,IV	−0.620	<.001	6	view →
STAD	All	II,III,IV	+0.681	.014	4	view →
LUAD	All	All	−0.426	<.001	4	view →
CHOL	Female	All	+3.086	<.001	3	view →
PRAD	All	All	+0.446	.001	2	view →
UCEC	All	All	−0.414	.042	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ADCY6–LIHC

Open the LIHC breakdown →